NithyaRamnathMD

Oncology • Ann Arbor, MI

Physician

Join to view full profile

Dr. Ramnath is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ramnath's full profile

Already have an account?

Office
1500 East Medical Center Dr
B1 Floor Cancer Recp C
Ann Arbor, MI 48109
Phone+1 734-647-8902

Fax+1 734-936-9015

Summary

Dr. Nithya Ramnath is an oncologist in Ann Arbor, MI and is affiliated with multiple hospitals in the area, including University of Michigan Medical Center, Michigan Medicine, and Veterans Affairs Ann Arbor Healthcare System. She received her medical degree from Jawaharlal Institute of Postgraduate Medical Education and Research and has been in practice 28 years. She specializes in hematologic oncology and is experienced in thoracic oncology and general medical oncology.

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1994 - 1996
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1992 - 1994
Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 1989

Certifications & Licensure

MI State Medical License 1994 - 2027
NY State Medical License 1999 - 2008
TX State Medical License 1996 - 2000
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors Start of enrollment: 1999 Mar 01
Completed
Phase 1
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors Start of enrollment: 2001 Aug 01
Completed
Phase 1
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 2
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery Start of enrollment: 2000 Mar 01
Completed
Phase 2
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2006 Oct 01
Terminated
Phase 2
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Phase I/II Calcitriol in Lung Cancer Start of enrollment: 2008 Dec 01
Terminated
Phase 1, Phase 2
A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer Start of enrollment: 2011 May 01
Terminated
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC Start of enrollment: 2015 Oct 01
Completed
Early Phase 1
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2018 Dec 24
Active, not recruiting
Phase 1, Phase 2
Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy Start of enrollment: 2021 Jul 07
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

30 citations
Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
Xuan Chen, Alison H Affinati, Yungchun Lee, Adina F Turcu, Norah Lynn Henry
Diabetes Care. 2022-05-01
121 citations
Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.
Vasudha Murlidhar, Rishindra M. Reddy, Shamileh Fouladdel, Lili Zhao, Martin K. Ishikawa
Cancer Research. 2017-09-15
54 citations
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
Angel Qin, David G. Coffey, Edus H. Warren, Nithya Ramnath
Cancer Medicine. 2016-09-01

Press Mentions

Vitamin D Linked to Lung Cancer Survival, Study SuggestsMarch 1st, 2011
Scientists 'Farm' Natural Killer Cells in Novel Cancer Fighting ApproachJanuary 29th, 2021
How to Reduce Health Care’s Climate Impact? Increase TelehealthJune 7th, 2024

Grant Support

The Role Of Vitamin D Metabolism In Non-Small Cell Lung CancerVeterans Affairs2011
A Phase I/II Clinical Trial Of Intravenous (I.V.) Calcitriol With Fixed Doses OfNational Cancer Institute2008–2009
A Phase I/II Clinical Trial Of Intravenous (I.V.) Calcitriol With Fixed Doses OfNational Cancer Institute2008